里昂发表研究报告，维持药明康德"跑赢大市"评级，目标价上调至143.4港元。里昂预期，药明康德将 受益于外包需求回暖及政策不确定性减弱，2026年盈利将明显增长。报告提及，2026年第一季度有三大 催化剂可能推动药明康德股价表现，包括1月12至15日的行业峰会，将更新CRO行业的最新展望，预计 将提振市场信心。其次，1月至2月间公布美国国防部1260H清单，有望减轻市场对政策的不安情绪。最 后，公司在3月的2026全年业绩指引，将进一步确认其盈利增长潜力。 ...

融资方面，近岸蛋白当日融资买入85.11万元。当前融资余额5693.89万元，占流通市值的4.35%，融资 余额低于近一年10%分位水平，处于低位。 分红方面，近岸蛋白A股上市后累计派现7017.54万元。 融券方面，近岸蛋白12月31日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，苏州近岸蛋白质科技股份有限公司位于江苏省苏州市吴江经济技术开发区云创路228号3层,4 层，成立日期2009年9月7日，上市日期2022年9月29日，公司主营业务涉及靶点及因子类蛋白、重组抗 体、酶及试剂的研发、生产、销售，并提供相关技术服务。主营业务收入构成为：靶点及因子类蛋白 58.04%，酶及试剂25.63%，CRO服务11.87%，重组抗体2.67%，其他(补充)1.79%。 截至11月10日，近岸蛋白股东户数6056.00，较上期减少0.53%；人均流通股5395股，较上期增加 0.53%。2025年1月-9月，近岸蛋白实现营业收入1.12亿元，同比增长21.48%；归母净利润-2885.93万 元， ...

【导读】百花医药或易主，自12月29日开市起停牌 2024年12月2日，米在齐、米恩华、杨小玲及其一致行动人李建城签署《一致行动人协议书》，有效期 一年，合计持有百花医药24.58%的股份。 中国基金报记者 闻言 12月26日晚间，百花医药发布公告称，公司控股股东、实际控制人米在齐、米恩华、杨小玲正在筹划公 司股份协议转让事宜，可能导致公司控制权发生变更。 百花医药计划自12月29日开市起停牌，预计停牌时间不超过2个交易日。12月26日收盘，百花医药股价 报12.24元/股，涨幅达5.88%，总市值为47.07亿元。 筹划股份转让前解除一致行动关系 公告显示，2025年12月1日，米在齐、米恩华、杨小玲及其一致行动人李建城确认不再续签《一致行动 人协议书》，一致行动关系自动解除。 如今，米在齐、米恩华、杨小玲仍为百花医药控股股东、实际控制人，李建城不再是百花医药控股股 东、实际控制人之一致行动人，其所持百花医药股份不再合并计算。 米在齐是米恩华、杨小玲夫妇之子。截至2025年12月1日，米在齐、米恩华、杨小玲合计持有百花医药 20.68%的股份。 具体来看，米在齐、米恩华、杨小玲直接持有百花医药股份的比例分别 ...

Group 1 - Lithium mining stocks experienced a significant surge, with futures rising over 6%, positively impacting the stock sector [2] - The white liquor industry is facing a downturn, with decreasing consumption and an unfavorable market environment, suggesting that the sector has not yet reached its bottom [3] - The Contract Research Organization (CRO) sector showed a rebound yesterday, but there is a preference to remain cautious and wait for better entry points [4]

格隆汇12月24日丨和元生物(688238.SH)在投资者互动平台表示，公司专注于细胞和基因治疗 CRO/CDMO业务，公司持续保持对包括欧盟市场在内的海外业务拓展，目前已有少量CRO服务订单实 现对欧盟国家的出口。 ...

Market Overview - A-shares and Hong Kong stocks are showing a weak trend, diverging from the rising prices of precious metals like platinum, lithium carbonate, gold, and silver, indicating a lack of alignment with the global "double holiday market" [3] - The volatility of the Shanghai Composite Index has been significantly lower than that of US and European markets in recent years, reflecting the complex structure of investors in the Chinese stock market [3] Investment Opportunities - **Humanoid Robots**: The upcoming New Year events are expected to feature humanoid robots, which may boost sales for related companies, although the impact on stock performance may be limited [4] - **Innovative Drugs and CROs**: The pharmaceutical sector remains stable, with year-end reports likely to prompt investment in pharmaceutical stocks as a means to stabilize financial expectations for investment funds [4] - **New Consumption, Especially Service Consumption**: The focus for 2026 is on stimulating consumption, particularly in the service sector, with potential growth in entertainment industries such as mobile games, live streaming, movies, and short dramas [6] - **Cyclical Non-ferrous Stocks**: The current environment of monetary easing is expected to continue, supporting the commodities market through at least the second half of next year [6]

Group 1 - The stock price of Nearshore Protein increased by 5.23% to 41.68 CNY per share, with a trading volume of 16.58 million CNY and a turnover rate of 1.26%, resulting in a total market capitalization of 2.925 billion CNY [1] - Suzhou Nearshore Protein Technology Co., Ltd. was established on September 7, 2009, and went public on September 29, 2022. The company specializes in the research, development, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with providing related technical services [1] - The revenue composition of the company's main business includes: target and factor proteins (58.04%), enzymes and reagents (25.63%), CRO services (11.87%), recombinant antibodies (2.67%), and other (1.79%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under China Merchants Fund holds a significant position in Nearshore Protein. The fund, China Merchants Anze Stable Profit 9-Month Holding Period Mixed A (019698), held 156,100 shares in the third quarter, accounting for 0.8% of the fund's net value, making it the fourth-largest holding [2] - The fund has a current scale of 516 million CNY and has achieved a return of 11.05% this year, ranking 5426 out of 8098 in its category. Over the past year, it has returned 10.29%, ranking 5409 out of 8067, and since its inception, it has returned 20.01% [2] Group 3 - The fund managers of China Merchants Anze Stable Profit 9-Month Holding Period Mixed A are Teng Yue and Wang Juanjuan. Teng Yue has a tenure of 8 years and 286 days, managing assets totaling 24.98 billion CNY, with the best fund return during his tenure being 51.01% and the worst being -3.32% [3] - Wang Juanjuan has a tenure of 3 years and 355 days, managing assets totaling 28.123 billion CNY, with the best fund return during her tenure being 22.78% and the worst being 1.23% [3]

Group 1 - The core viewpoint is that innovative drug commercial insurance is expected to alleviate the medication burden on patients and open new market channels for pharmaceutical companies, thereby enhancing confidence in R&D for innovative drugs within the industry [1] - The company, as a specialized CRO service provider, is likely to gain more new drug R&D projects and orders [1]

Group 1 - The core viewpoint of the article is that Jiuzhou Pharmaceutical is actively expanding its global market presence by establishing a wholly-owned subsidiary in Japan to invest in a CRO service platform, with positive business progress and growth in both clients and projects [1] Group 2 - The company plans to set up the subsidiary in early 2024 [1] - The business development is reported to be progressing smoothly, indicating a favorable operational environment [1] - There is a notable increase in both the number of clients and projects, reflecting strong demand and growth potential [1]

Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]